Skip to main content

Market Overview

Vascular Biogenics: Q3 Earnings Insights



Shares of Vascular Biogenics (NASDAQ:VBLT) moved higher by 0.8% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 14.29% year over year to ($0.12), which beat the estimate of ($0.13).

Revenue of $193,000 higher by 144.30% from the same period last year, which beat the estimate of $170,000.


Vascular Biogenics hasn't issued any earnings guidance for the time being.

Vascular Biogenics hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Nov 16, 2020

Time: 08:30 AM

ET Webcast URL:


Company's 52-week high was at $1.64

52-week low: $0.90

Price action over last quarter: down 7.76%

Company Profile

Vascular Biogenics Ltd is an Israel-based clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.


Related Articles (VBLT)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at